Zasocitinib

Takeda’s oral TYK2 inhibitor, zasocitinib, demonstrated strong efficacy in Phase 3 psoriasis trials, meeting all primary and secondary endpoints. The drug achieved significant skin clearance, with many patients experiencing substantial improvement and complete skin clearance by week 16. Zasocitinib showed a consistent safety profile and is poised for regulatory submission in fiscal year 2026, offering a promising new oral treatment option for moderate-to-severe plaque psoriasis.